Bioson Group and Boryung Sign MOU for Domestic Commercialization of 'Opiranezin'

(From left) Lee Doohyun, Chairman of Vivoson; Jang Doohyun, CEO of Boryung; Jang Buhwan, CEO of Vivoson Pharmaceuticals. / Photo by Vivoson Pharmaceuticals

Bioson Group and Boryung (formerly Boryung Pharmaceutical) will collaborate to commercialize Ophirangerin domestically and discuss strategic partnership plans for their new drug pipeline.

On the 3rd, Bioson and Bioson Pharmaceutical announced that they signed a memorandum of understanding (MOU) with Boryung for the domestic commercialization of Onapraju (generic name Ophirangerin). They will also discuss strategic partnerships and investments for the pipelines under development by Bioson Group, as well as cooperation plans for products from both companies.

Ophirangerin is a non-opioid analgesic developed independently by Bioson using a multi-target new drug discovery platform, intended for postoperative pain. It is a domestically produced new drug proven effective through a Phase 3 clinical trial in Korea and is expected to receive approval from the Ministry of Food and Drug Safety (MFDS) this year. After obtaining MFDS approval, Bioson Group will provide Ophirangerin in finished product form to Boryung, and both companies will share roles in distribution and sales.

They will also discuss cooperation plans for other pipelines under development by Bioson. This includes strategic partnerships involving Boryung’s investment and technology transfer for Bioson’s follow-up pipelines such as VVZ-2471, an oral analgesic and candidate drug for addiction treatment.

Lee Doohyun, Chairman of Bioson, said, “Boryung is a leading domestic pharmaceutical company with extensive new drug development experience and a solid sales and marketing network. We will actively cooperate with Boryung for the successful commercialization of Ophirangerin and the development of subsequent products.” He added, “We will also begin in-depth discussions on ways to create synergy through strategic partnerships for the next pipeline.”

Jang Doohyun, CEO of Boryung, stated, “Based on Boryung’s new drug development experience and accumulated research, development, and sales marketing capabilities, we will accelerate the development and commercialization of Ophirangerin. We will continue to actively cooperate with Bioson Group in various fields, including follow-up pipelines.”